Objective To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine
reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major …

Objective To examine the safety and tolerability of the antidepressant duloxetine across
multiple studies for major depressive disorder (MDD). Method Safety data were integrated from …

The primary objectives of this study were to assess the efficacy and safety of duloxetine for
reducing pain severity in fibromyalgia patients with or without current major depressive …

Background: Depression is a chronic disease consisting of emotional/psychological and
physical symptoms. Emotional symptoms have been shown to respond to currently available …

Background: While emotional symptoms such as depressed mood and loss of interest have
traditionally been considered to constitute the core symptoms of major depressive disorder (…

Objective: The goal of a non-inferiority study is to test whether a new treatment has at least
as much efficacy as an established treatment 1 . The purpose of this non-inferiority study was …

… Wohlreich are stock shareholders and full-time employees of Eli Lilly and Company. Dr.
Clayton is a consultant for Boehringer Ingelheim, BristolMyersSquibb, Eli Lilly and Company, …

… Also excluded were patients who had another chronic painful condition such as fibromyalgia
that could interfere with assessment of the knee, those with a body mass index >40 kg/m 2 , …

Objective: To investigate the efficacy of duloxetine in the treatment of pain and improvement
in functional impairment and quality of life in patients with fibromyalgia from a pooled …

Objective. To investigate the efficacy of flexible dose duloxetine 60–120 mg/day on changes
in fibromyalgia (FM) symptoms assessed by the Patient Global Impression of Improvement (…